• Anlotinib Hydrochloride as a Selective VEGFR2 Inhibitor in A

  2026-06-23

  The reference study characterizes anlotinib hydrochloride as a highly potent and selective inhibitor of VEGFR2, demonstrating superior anti-angiogenic activity in both in vitro and in vivo models. Its innovation lies in its selectivity and broad antitumor efficacy, providing a valuable tool for cancer research targeting angiogenesis.

• Perospirone Inhibits Vascular Kv1.5 Channels: Mechanistic In

  2026-06-23

  A 2025 study reveals that Perospirone, beyond its established antipsychotic receptor activity, inhibits vascular Kv1.5 potassium channels in a concentration-dependent and use-independent manner. These findings expand our mechanistic understanding of Perospirone and highlight its relevance for both neuropsychiatric disorder models and cardiovascular research.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-06-22

  Anlotinib hydrochloride redefines angiogenesis and tumor growth assays with unmatched multi-target kinase inhibition. Discover stepwise experimental workflows, troubleshooting strategies, and comparative performance insights that accelerate cancer research using APExBIO's optimized compound.

• Thiamet G: O-GlcNAcase Inhibitor for Advanced O-GlcNAc Resea

  2026-06-22

  Thiamet G empowers researchers to precisely elevate O-GlcNAcylation, enabling transformative workflows across neurodegeneration, leukemia, and bone biology. Its high potency, robust solubility, and proven in vivo stability make it the gold standard for dissecting post-translational modifications in disease models.

• Olaparib (AZD2281) Workflows for DNA Damage Response Assays

  2026-06-21

  Olaparib (AZD2281) empowers precision DNA damage response assays and tumor radiosensitization studies, especially in BRCA-deficient cancer models. This guide delivers actionable workflows, troubleshooting strategies, and evidence-driven tips to maximize experimental reliability in cancer research.

• Nonselective β-Blockers Impair Hematopoietic Regeneration Po

  2026-06-20

  This study demonstrates that nonselective β-adrenergic receptor antagonists such as Carvedilol significantly delay hematopoietic recovery following allogeneic hematopoietic cell transplantation (HCT) in both mice and human patients. The findings highlight the mechanistic distinction between nonselective and β1-selective β-blockers, underscoring important translational implications for transplant management.

• 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole: Applied Workf

  2026-06-19

  5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) offers precise inhibition of transcriptional elongation, making it invaluable for dissecting RNA synthesis and antiviral mechanisms in cellular models. This article translates cutting-edge research and validated protocols into actionable guidance, bridging advanced stem cell biology and viral studies for maximum experimental impact.

• CP-673451 in Translational Cancer Research: Mechanism, Impac

  2026-06-19

  Explore the mechanistic and translational advantages of CP-673451, a selective PDGFRα/β inhibitor, in preclinical models of tumor angiogenesis and growth. Integrating recent findings on ATRX-deficient glioma sensitivity, this article provides strategic guidance for researchers leveraging targeted kinase inhibition in advanced cancer studies.

• Decoding Mutational Landscapes in Myeloma Cell Lines: Driver

  2026-06-18

  This article explores a comprehensive exome sequencing study of multiple myeloma cell lines, revealing key mutated genes and pathways linked to tumor progression and drug resistance. The findings refine model selection for myeloma research and underscore the importance of genetic context in evaluating candidate therapeutics such as Pomalidomide (CC-4047).

• JNJ-10198409: PDGF Receptor Inhibitor for Angiogenesis Resea

  2026-06-18

  JNJ-10198409 is a potent platelet-derived growth factor receptor inhibitor with nanomolar activity, blocking PDGF-BB receptor-mediated signaling pathways. This specificity enables rigorous study of tumor growth inhibition by PDGF blockade and antiangiogenic mechanisms in vitro and in vivo. APExBIO supplies JNJ-10198409 for research applications requiring reliable PDGF pathway modulation.

• Arginine Methylation, FUS-SMN Interactions, and Neuronal Gra

  2026-06-17

  The study by Wang and Li (2024) elucidates how arginine methylation of FUS facilitates its phase separation with SMN, critical for neuronal granule assembly. These findings deepen our understanding of post-translational modifications in neurodegenerative disease mechanisms and inform advanced RNA labeling approaches for related molecular investigations.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody: Technical Protocol G

  2026-06-17

  The Cy3 Goat Anti-Mouse IgG (H+L) Antibody provides sensitive, specific detection of mouse IgG primary antibodies in research immunoassays, including immunofluorescence, western blotting, and flow cytometry. It is not suitable for diagnostic or clinical applications. Researchers benefit from its signal amplification capabilities, but must adhere to recommended storage and handling to maintain performance.

• Mutational Landscape of Myeloma Cell Lines: Insights for Dru

  2026-06-16

  This study delivers a comprehensive exome-wide characterization of 30 human multiple myeloma cell lines, mapping key mutations and pathways linked to tumor progression and drug resistance. Its findings provide a rational foundation for selecting preclinical models and inform the design of more targeted therapeutic strategies in hematological malignancy research.

• Topological Stress Drives Persistent rDNA Damage and PML-Nuc

  2026-06-16

  This study uncovers how topological stress and inhibition of RNA polymerase I trigger persistent DNA double-strand breaks in ribosomal DNA, leading to the assembly of PML-nucleolar compartments (PNAs). The findings clarify the molecular pathways linking nucleolar DNA damage, PML body dynamics, and cellular senescence, with implications for genome stability and cancer biology.

• UHRF1-Driven 5-mC Alters Super-Enhancers in Senile Osteoporo

  2026-06-15

  This study reveals that UHRF1-mediated DNA 5-methylcytosine modification disrupts super-enhancer architecture, impairing osteogenic differentiation in senile osteoporosis through the TGM2-autophagy axis. These findings establish a direct mechanistic link between DNA methylation, enhancer remodeling, and stem cell dysfunction, indicating new epigenetic intervention points for age-related bone loss.

16639 records 1/1110 page Next 12345 下5页 Last page